ArticleHerz2013
Increased H-FABP concentrations in nonalcoholic fatty liver disease. Possible marker for subclinical myocardial damage and subclinical atherosclerosis.
Article in Herz, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Non-alcoholic fatty liver disease increases risk of carotid atherosclerosis and ischemic stroke: An updated meta-analysis with 135,602 individuals.Clinical and molecular hepatology · 2022Pooled it
- Myocardial injury associated with naturally occurring clinical bovine anaplasmosis: evaluation of novel cardiac biomarkers.Veterinary research communications · 2026Article
- H-FABP and Hs-cTnI Serum Concentrations Associate with the Development of Cardiovascular Events in Newly Diagnosed T2D, Pre-DM, and Normoglycemic Individuals.Vascular health and risk management · 2025Article
- Association of nonalcoholic fatty liver disease and carotid media-intima thickness: A systematic review and a meta-analysis.Health science reports · 2023Article
- Fatty Acid Binding Proteins 3 and 4 Predict Both All-Cause and Cardiovascular Mortality in Subjects with Chronic Heart Failure and Type 2 Diabetes Mellitus.Antioxidants (Basel, Switzerland) · 2023Article
- FABP3, FABP4, and heart rate variability among patients with chronic schizophrenia.Frontiers in endocrinology · 2023Article
- Fatty Acid-Binding Proteins in Psoriasis-A Review.Metabolites · 2022Review
- Review
- Association of plasma fatty acid-binding protein 3 with estimated glomerular filtration rate in patients with type 2 diabetes mellitus.International journal of medical sciences · 2022Article
- Modulation of endothelium function by fatty acids.Molecular and cellular biochemistry · 2022Review
- H-FABP: A beacon of hope for prediabetic heart disease.Journal of family medicine and primary care · 2020Article
- Circulating Cardiac Biomarkers in Diabetes Mellitus: A New Dawn for Risk Stratification-A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2020Review
- Novel Invasive and Noninvasive Cardiac-Specific Biomarkers in Obesity and Cardiovascular Diseases.Metabolic syndrome and related disorders · 2020Review
- Discovery of potential plasma protein biomarkers for acute myocardial infarction via proteomics.Journal of thoracic disease · 2019Article
- Level of FABP3, FABP4, Nt-proBNP and Total Cardiovascular Risk in the Population of Central Kazakhstan.Open access Macedonian journal of medical sciences · 2017Article
- Heart-type fatty acid binding protein levels in elderly diabetics without known cardiovascular disease.Clinical interventions in aging · 2017Article
- Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis.Lipids in health and disease · 2015Review
- E2F8 promotes hepatic steatosis through FABP3 expression in diet-induced obesity in zebrafish.Nutrition & metabolism · 2015Article
- Serum H-FABP levels in patients with hypothyroidism.Wiener klinische Wochenschrift · 2014Article
- Roles of chronic low-grade inflammation in the development of ectopic fat deposition.Mediators of inflammation · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimNonalcoholic fatty liver disease (NAFLD) is the most common liver disorder which is reported as the hepatic manifestation of metabolic syndrome with an increased risk of cardiovascular events. Patients with NAFLD are also at risk of future cardiac events independently of metabolic syndrome. The aim of this study was to examine serum concentrations of heart type fatty acid binding protein (H-FABP) in NAFLD and to investigate its correlations with metabolic parameters and subclinical atherosclerosis. PATIENTS AND
methodsA total of 34 patients with NAFLD and 35 healthy subjects were enrolled in the study. NAFLD patients had elevated liver enzymes and steatosis graded on ultrasonography. Healthy subjects had normal liver enzymes and no steatosis on ultrasonography. H-FABP levels were measured using an enzyme linked immunosorbent assay (ELISA) method and correlations with metabolic parameters and subclinical atherosclerosis were examined. Subclinical atherosclerosis was determined with carotid artery intima-media thickness (CIMT) which was measured by high resolution B mode ultrasonography.
resultsH-FABP levels were elevated in patients with NAFLD (16.3 ± 4.0 ng/ml) when compared with healthy controls (13.8 ± 2.1 ng/ml; p < 0.001). NAFLD patients had significantly higher CIMT than the controls had (0.64 ± 0.17 mm vs. 0.43 ± 0.14 mm, p = 0.009). The H-FABP concentrations were significantly positively correlated with body mass index (r = 0.255, p = 0.042), fasting blood glucose level (r = 0.300, p = 0.013), CIMT (r = 0.335, p = 0.043), and homeostasis model assessment-estimated insulin resistance (HOMA-IR; r = 0.156, p = 0.306). In multiple linear regression analysis, H-FABP levels were only independently associated with CIMT (p = 0.04)
conclusionSerum H-FABP concentrations increase in patients with NAFLD. Our results may not only suggest that H-FABP is a marker of subclinical myocardial damage in patients with NAFLD but also of subclinical atherosclerosis, independent of metabolic syndrome and cardiac risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.